Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Table 2 The efficacy analysis

Best Overall Response	Intention-to-treat population(n = 115)	Per-protocol population (N = 92^a)
Complete remission, No. (%)	2 (1.73%)	2 (21.7%)
Partial remission, No. (%)	41 (35.65%)	41 (44.5%)
Stable disease, No. (%)	32 (27.82%)	32 (34.7%)
Disease progression No. (%)	17 (14.7%)	17 (18.4%)
ORR^b, (95%CI)	37.4% (28.4–46.4%)	46.7% (36.3–57.1%)
DCR^c, (95%CI)	65.2% (56.4–74.1%)	81.5% (73.4–89.6%)

ORR Objective response rate, DCR Disease control rate; ^a Fourteen patients receiving less than 2 cycles of PLD and 7 patients without efficacy assessments after 2 cycles of PLD were excluded. Moreover,2 patients had a postbaseline efficacy assessment that could not be confirmed and thus were excluded; ^b Including patients with complete and partial responses; ^c Including patients with complete and partial responses and stable disease

ISSN: 1757-2215